Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord MSCs for HIV Immune Non-Responders
NCT05872659Phase 1Recruiting
- Sponsor
- Shandong Qilu Stem Cell Engineering
- Start
- Apr 2023
- Primary completion
- Nov 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Shandong Qilu Stem Cell Engineering. Primary endpoint: Change in CD4+ T cell counts at 12 months. Started Apr 2023; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05872659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872659.